Nisha A. Mohindra, MD
With the development of selective TKIs, it’s no longer a question of whether ALK
-positive and ROS1
-positive non–small cell lung cancer (NSCLC) can be targeted, but rather how to select the optimal therapy among a growing roster of treatments, according to Nisha A. Mohindra, MD.
... to read the full story